The DEA has given Epidiolex, the CBD-based pharmaceutical derived from cannabis that was approved by the FDA for the treatment of rare forms of epilepsy in June, Schedule V status
Growth Capitalist (https://growthcapitalist.com/2018/09/dea-green-lights-epidiolex-as-first-cannabis-derived-pharmaceutical/)
The DEA has given Epidiolex, the CBD-based pharmaceutical derived from cannabis that was approved by the FDA for the treatment of rare forms of epilepsy in June, Schedule V status